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Abstract: A series of fifteen novel gallic acid esters (7a-o) was synthesized and structure was confirmed by spectral data. Antibiotic power of 
compounds was assessed against a panel of ten microbes while antioxidant activity was gauged by employing DPPH, ABTS and antilipid 
peroxidation assays. It was found that in comparison to lead, many of the synthesized derivatives implied much improved broad spectrum 
antimicrobial effect. Most effective compound found was 7c specifically against resistant gram-negative strains such as P. aeruginosa, E. coli 
and E. aerogenes. Potent antioxidant capacity was exhibited by7a and 7d in electron transfer assays while 7j and 7c provided maximum shielding 
against lipid peroxidation. Structure-activity analysis revealed that analogues with electron -withdrawing substituent particularly chloro group 
stand out as much better antibiotic agent. This study suggests that halogenated gallic acid analogues might be promising pharmacological 
candidates in view of further drug development. 
 





ICROBIAL infections are a serious problem that 
continues to challenge healthcare sector in both 
developed and developing countries. Microbes produce a 
series of diseases ranging from various invasive skin 
infections to fatal life threatening ailments especially in the 
patients of organ transplant, acquired immunodeficiency 
syndrome and cancers. Drug resistance in hospitals and 
communities has further complicated the treatment.[1] 
Regardless of advancements in antibiotic therapy, 
infectious complications are one of the most imperative 
causes of high rate of morbidity and mortality among 
hospitalized patients. Under these circumstances there is a 
dire need for the development of new potent 
antimicrobials. Owing to enormous chemical and structural 
diversity, pharmacologically active plant derived natural 
products that has inspired novel drug discoveries in the 
past could be a promising source in various medical areas. 
Most of the clinical antimicrobial therapeutics are either of 
natural origin or their semisynthetic derivatives.[2,3] 
 Free radicals mediated oxidative stress has been 
established as a triggering point for multiple medical 
conditions such as asthma, arthritis, neurodegenerative 
disorder, cardiovascular diseases and some cancers via 
inflammation.[4−6] Additionally, reactive oxygen species 
(ROS) are major factor in progression of inflammation 
through the release of cytokines. Antioxidants play key role 
in management of such conditions by neutralizing active 
species therefore inversing the oxidative stress. Hence it is 
very important to search for natural sources of antioxidants 
to promote public health. It is assumed those natural 
products or their derivatives, having potent antioxidant 
activity can relief cellular oxidative stress and may serve as 
leads for the development of novel drugs or as 
supplements for the prevention of many diseases.[7] 
 Gallic acid (GA), 3, 4, 5-trihydroxy benzoic acid, is a 
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kingdom. It is important bioactive secondary metabolites of 
various medicinal plants and is widely used in 
Homeopathic, Ayurveda, Unani and African traditional drug 
formulations. This natural compound, we isolated from the 
bark of Terminalia bellerica in continuation of our search 
for pharmacologically active natural products from native 
plants, has been speculated as a major contributor of 
therapeutic power of medicinal plants. According to 
literature reports, GA has been studied extensively in vitro 
as well as in vivo for various bioactivities such as 
antioxidant, antiviral, antibacterial and antifungal, 
hepatoprotective, neuroprotective, antidiabetic, 
anticancer against various cell lines, antitumor, analgesic 
and enzyme inhibition.[8−16] Being biocompatible and 
environment friendly it has found wide applications in 
pharmaceutical, food and cosmetic industries. For drug 
innovation, structural modifications of natural products are 
necessary as secondary metabolites are produced by the 
living organisms for self-defense against enemies and 
environment. Natural product based drug discovery 
demands manipulation and modification of the structure of 
active compound to reach drug criterion. In this regard, GA 
derivatives especially esters have been synthesized and 
evaluated for various biological activities. For instance alkyl 
esters of GA with long alkyl chains have shown substantial 
antioxidant potential.[17] Similarly herpes simplex virus type 
1 (HSV-1) was highly susceptible to GA alkyl esters. 
Cytotoxic potential of gallate esters against B16F10 
melanoma cell line was investigated and it was found that 
they dwindled the strong antioxidant defense of cancer 
cells and induced apoptosis by elevating oxidative stress 
within the cells.[18] 
 Inspired by significant antimicrobial and antioxidant 
activity of GA derivatives, a series of novel gallic acid esters 
is synthesized in view of to augment its therapeutic power 
and get better antimicrobial and antioxidant agents. In 
present work novel alkyl as well as aryl ester derivatives 
with variable substituent are synthesized and assessed 
thoroughly against a panel of microbes. Standard 
antioxidant protocols are employed in consideration to get 
better antioxidant entities. 
 
EXPERIMENTAL SECTION 
General Experimental Procedures 
Gallenkamp apparatus was used to measure melting points 
(mp) which are uncorrected. IR spectra were obtained on 
KBr plates on FTIR modelM2000, medacMidac cooperation 
USA. UV/VIS absorbance was recorded on U-2800 
spectrophotometer (Hitachi). Nuclear magnetic resonance 
(NMR) spectra were recorded on Bruker Avance II 500 
spectrometer at 500 MHz (1H NMR), 125.77 MHz (13C NMR) 
in methanol-d6 or CDCl3 containing TMS as internal 
standard. Mass spectra were obtained on a JEOL JMS-HX-
110 instrument, in the positive ion mode. Column 
chromatography (CC) was performed on silica gel (70–230 
mesh) from E. Merck. Flash silica CC was done with silica gel 
(40–63µm) (Silicycle, Canada). Analytical thin layer 
chromatography (TLC) was performed on TLC plates (silica 
gel 60 F254, aluminum back, Merck). All the compounds used 
were either from Sigma-Aldrich (St. Louis, MO, USA) or 
ACROS ORGANICS. Cell culture media and antibiotics were 
obtained from GIBCO while microbial culture media and 
antibiotics were gained from Oxiod (Basingstoke, UK). All 
solvents were obtained from Merck and distilled before use 
except HPLC grade solvents. 
Derivatization of Gallic acid (3,4,5-
trihydroxybenzoic acid) 
Synthesis of Propyl 3, 4, 5-trihydroxybenzoate (2)[19] 
Propyl 3,4,5-trihydroxybenzoate was prepared by 
dissolving GA (1) (1.0 g, 5.8 mmol) in propyl alcohol (15.0 
ml) in a single neck round bottom flask. Thionyl chloride 
(0.9 ml, 2.4 mmol) was added dropwise along with stirring 
at 0oC. Reaction mixture was refluxed at 70oC for 5-6 h 
under nitrogen atmosphere and monitored by TLC. Solid 
product was obtained by removing solvent with the help of 
rotary evaporator. It was redissolved in EtOAc and washed 
with NaHCO3 solution (3×20.0 ml), brine solution (2×20.0 
ml) and finally with water. EtOAc layer was dried over 
sodium sulphate and then under nitrogen at rt. Pure propyl 
3, 4, 5-trihydroxy benzoate was obtained by a column wash 
using Pet ether :EtOAc (1 : 1) solvent mixture. m.p. 146−148 
°C; yield: 73 %; IR (KBr), ῦ/cm−1: 3445 (OH), 3030 (sp2 CH), 
1740 (C=O), 1625, 1495 (C=C), 1240 (C-O); 1H NMR 
(methanol-d6, 500 MHz) δ/ppm: 1.04 (t, 3H, J = 7.4 Hz, CH3), 
1.77 (m, 2H, CH2), 4.20 (t, 2H, J = 6.6 Hz, OCH2), 7.08 (s, 2H, 
H2 & H6 ); 13C NMR (methanol-d6, 125 MHz ) δ/ppm: 10.12 
(C10), 22.59 (C9), 67.13 (C8), 110.67(C2/C6), 122.45 (C1), 
139.54 (C4), 146.81 (C3/C5), 167.26 (C7);HR-ESI-MS: m/z = 
213.40[M+H]+. 
 
Synthesis of Propyl 3, 4, 5-tribenzyloxybenzoate (3)[20] 
Benzyl chloride (4.6 ml, 40.0 mmol) was added to a solution 
of compound 2 (2.2g, 1.0×10−5 mmol) in DMF (20.0 ml) in a 
three necks round bottom flask. Potassium carbonate 
(5.0g, 3.6×10−5 mmol) was mixed with continuous stirring 
to reaction mixture and it was refluxed on an oil bath for 4 
h. Water (40.0 ml) was then poured in the mixture and 
cooled in ice. Crude product was filtered and dried under 
nitrogen. Recrystallization of crude product by Hex : 
benzene (1:2) gave pure colorless powder of propyl-3, 4, 5-
tribenzyloxybenzoate. m.p. 150−152 °C; yield: 73 %; IR (KBr) 
ῦ/cm−1: 3020 (sp2 CH), 1738 (C=O), 1610, 1490 (C=C), 1240 
(C-O); 1H NMR ( CDCl3, 500 MHz ) δ/ppm: 0.88 (t, 3H, J = 7.4 
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OCH2), 5.00 (d, 6H, J = 6.8 Hz, OCH2 x 3), 7.26 (m, 17H, ArH); 
13C NMR (CDCl3, 125 MHz ) δ/ppm: 7.55 (C9), 10.31(C10), 
22.78 (C8), 71.23 (O−CH2), 109.78 (C2/C6), 124.52 (C1), 
127.21 (C2′/C6′), 127.79 (C4′), 129.45 (C3′/C5′), 136.85 (C1′), 
143.24 (C4), 152.67 (C3/C5), 167.78 (C7); HR-ESI-MS: m/z = 
213.27[M+H]+. 
 
Synthesis of 3,4,5-tribenzyloxybenzoic acid (4)[20] 
Sodium hydroxide (0.42 g, 10.5 mmol) was added in three 
portions to a solution of compound 3 (1.5 g, 3.5 mmol) in 
methanol (40.0 ml). Water (2.0 ml) was added and refluxed 
on an oil bath for 4 h. It was cooled and water (100 ml) was 
added again, followed by acidification with HCl (36 %). 
Product was filtered, washed with water and recrystallized 
with ethanol to get 3,4,5-tribenzyloxybenzoic acid. 
Synthesized compound was obtained as colorless powder. 
m.p. 188 °C; yield, 85 %; IR (KBr) ῦ/cm−1: 3485 (OH), 3010 
(sp2 CH), 1705 (C=O), 1600, 1490 (C=C); 1H NMR (CDCl3, 500 
MHz) δ/ppm: 4.96 (d, 6H, J = 4.2 Hz, OCH2), 6.82 (s, 2H, H2 
& H6), 7.07 (s, 15H, ArH); 13C NMR (CDCl3, 125.0 MHz ) 
δ/ppm: 72.27 (OCH2 x 2), 71.43 (OCH2), 110.78 (C2/C6), 
127.23 (C2′/C6′), 128.42 (C4′), 128.92 (C3′/C5′), 141.27 (C1′), 
145.34 (C4), 151.62 (C3/C5), 170.56 (C7); HR-ESI-MS: m/z = 
441.52[M+H]+. 
 
Synthesis of 3, 4, 5-tribenzyloxybenzoyl chloride (5)[20] 
Compound 4 (1.23 g, 2.8 mmol) and thionyl chloride (95 
%, 4.2 ml, 58.0 mmol) were added to benzene (25.0 ml) in 
a completely dried flask. Pyridine (0.5 ml) was poured in 
the solution while stirring. Reaction mixture was refluxed 
for 3 h at 73 °C. Petroleum ether was added to this 
mixture and concentrated on rotary evaporator. This 
concentrated acid chloride was diluted with 10.0 ml 
chloroform and used immediately for coupling with 
respective alcohol or aniline. 
General Protocol for Gallic Acid Esters 
Synthesis (6a-6o) 
Ester derivatives were synthesized according to the 
reported procedure.[21] One half of the diluted solution 
of compound 5 (≈ 1 mmol) was added immediately after 
synthesis to the ice cold solution of respective coupling 
alcohol (1.5 mmol) and triethylamine (3.0 mmol) in 
anhydrous chloroform (20.0 ml). It was brought to rt, 
followed by refluxing. TLC monitoring of the reaction was 
done with solvent system Pet. ether : Ethyl acetate (1 : 1). 
On completion, organic layer was washed with NaHCO3 
solution (3 × 20.0 ml), brine solution (2 × 20.0 ml) and 
finally with water (2 × 20.0 ml), followed by drying over 
sodium sulphate. Solvent was removed by rotary 
evaporator and pure product was obtained by CC (Hex : 
EtOAc 8 : 2). 
Debenzylation of Gallic Acid Esters  
(7a-7o)[22] 
In an oven-dried round bottom flask, benzylated ester (6a-
6o, 1.0 mmol) was dissolved in solvent mixture of 
chloroform and methanol (1:1). Palladium/ activated 
carbon (10.0 % Pd, 50.0 mg) were added to it. Air was 
evacuated from the flask by vacuum and reaction mixture 
was stirred at rt under hydrogen atmosphere. It was 
monitored by TLC using solvent system Hex : EtOAc (1:1). 
On completion, reaction mixture was filtered on celite and 
dried in rotary evaporator. Pure product was obtained by 
CC (Hex : EtOAc 9:1 → 8:2). 
 Spectroscopic data of the synthesized analogues is 
listed below. 
 
2,2,2-trichloroethyl 3, 4, 5-trihydroxybenzoate (7a) 
IR (KBr) ῦ/cm−1: 3510 (OH), 3010 (sp2 CH), 1739 (C=O), 1625 
(C=C), 1201 (CO); 1H NMR (methanol-d6, 500 MHz ) δ/ppm: 
4.86 (s, 2H, CH2), 6.80 (s, 2H, H2&H6); 13C NMR (methanol-
d6, 125 MHz ) δ/ppm: 75.82 (C8), 96.26 (C9), 110.41 ( C2& 
C6), 125.17 (C1), 140.74 (C4), 148.37 (C3&C5), 164.19 (C7); 
HR-ESI-MS: m/z = 302.59 [M+H]+. 
 
3-bromopropyl 3, 4, 5-trihydroxybenzoate (7b) 
IR (KBr) ῦ/cm−1: 3495 (OH), 3010 (sp2 CH), 2900 (sp3 CH), 
1739 (C=O), 1619 (C=C); 1H NMR (methanol-d6, 500 MHz) 
δ/ppm: 2.27( q, 2H, J = 1.6 Hz, CH2), 3.54 (t, 2H, J = 6.5 Hz, 
CH2X), 4.68 (t, 2H, J = 6.4 Hz, OCH2), 7.01 (s, 2H, H2&H6 ); 13C 
NMR ( methanol-d6, 125 MHz ) δ/ppm: 29.12 (C9), 31.86 
(C10), 63.39 (C8), 110.21 ( C2&C6), 126.68 (C1), 139.84 (C4), 
147.82 (C3&C5), 169.72 (C7); HR-ESI-MS: m/z = 292.21 
[M+H]+. 
 
3-chloropropyl 3, 4, 5-trihydroxybenzoate (7c) 
IR (KBr) ῦ/cm−1: 3485 (OH), 3012 (sp2 CH), 2905 (sp3 CH), 
1742 (C=O), 1604, 1499 (C=C); 1H NMR ( methanol-d6, 500 
MHz ) δ/ppm: 2.08 ( q, 2H, J = 6.3 Hz, CH2), 3.38 (t, 2H, J = 
5.8 Hz, CH2X ), 4.11 (t, 2H, J = 6.4 Hz, OCH2), 6.81 (s, 2H, 
H2&H6 ); 13C NMR ( methanol-d6, 125.0 MHz ) δ/ppm: 32.42 
(C9), 41.86 (C10), 62.39 (C8), 110.17 (C2&C6), 140.39 (C4), 
125.64 (C1), 147.28 (C3&C5), 168.27 (C7); HR-ESI-MS: m/z = 
247.74 [M+H]+. 
 
2,4-dinitrophenyl 3,4,5-trihydroxybenzoate (7d) 
IR (KBr) ῦ/cm−1: 3510 (OH), 1743 (C=O), 1590 (C=C), 1510, 
1335 (NO);1H NMR (methanol-d6, 500 MHz ) δ/ppm: 7.20 
(s, 2H, H2&H6 ), 7.71 (d, 1H, J = 8.5 Hz, H6´), 8.68 (dd, 1H, J = 
8.5 Hz, H5´), 9.09 (d, 1H, J = 2.6 Hz, H3´), 13C NMR (methanol-
d6, 125 MHz ) δ/ppm: 110.16 (C2&C6), 119.42 (C3′), 123.36 
(C6´), 125.77 (C1), 127.91 (C5´), 141.73 (C4), 143.18 (C2´), 
146.37 (C4´), 148.95 (C3&C5), 154.87 (C1´), 165.54 (C7); HR-
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4-bromophenyl 3, 4, 5-trihydroxybenzoate (7e) 
IR (KBr) ῦ/cm−1: 3492 (OH), 1743 (C=O), 1603, 1490 (C=C), 
1140 (CO); 1H NMR (methanol-d6, 500 MHz ) δ/ppm: 7.13 
(s, 2H, H2&H6 ), 7.16 (d, 2H, J = 8.0 Hz, H2′& H6′), 7.31 (d, 2H, 
J = 8.1 Hz, H3′& H5′); 13C NMR (methanol-d6, 125 MHz) 
δ/ppm: 110.18 (C2/C6), 119.82 (C4′), 123.15 (C2′&C6′), 126.47 
(C1), 130.32 (C3′&C5′), 141.49 (C4), 148.81 (C3&C5), 151.53 
(C1′), 160.75(C7); HR-ESI-MS: m/z = 326.21 [M+H]+. 
 
2,4-dibromophenyl 3, 4, 5-trihydroxybenzoate (7f) 
IR (KBr) ῦ/cm−1: 3490 (OH), 1740 (C=O), 1606, 1495 (C=C), 
1150 (CO); 1H NMR (methanol-d6, 500 MHz) δ/ppm: 6.59 (d, 
1H, J = 8.0 Hz, H6′), 7.15 ( s, 2H, H2& H6), 7.56 (dd, 1H, J = 8.0 
Hz, 1.5 Hz, H5′), 7.75 (d, 1H, J = 2.3 Hz, H3′); 13C NMR 
(methanol-d6, 125 MHz) δ/ppm: 108.32 (C2&C6), 124.67 
(C4′), 126.81 (C2′), 130.52 (C5′), 133.78 (C1), 134.53 (C6′), 
135.24 (C3′), 136.56 (C1′), 140.39 (C4), 148.22 (C3&C5), 
202.89 (C7); HR-ESI-MS: m/z = 405.21 [M+H]+. 
 
Naphthalen-1-yl 3, 4, 5-trihydroxybenzoate (7g) 
IR (KBr) ῦ/cm−1: 3443 (OH), 3040 (sp2 CH), 1740 (C=O), 1598 
(C=C), 1130 (CO); 1H NMR (methanol-d6, 500 MHz) δ/ppm: 
6.63 (d, 1H, J = 8.1 Hz, H2′), 6.82 (s, 2H, H2&H6), 7.11−7.17 
(m, 2H, H3′&H4′), 7.73 (d, 1H, J = 8.1 Hz, H5′), 7.34−7.38 (m, 
2H, H6′ & H7′), 8.09 (d, 1H, J = 7.8 Hz, H8′); 13C NMR 
(methanol-d6, 125 MHz) δ/ppm: 109.12 (C2′), 110.96 
(C2/C6), 121.12 (C4′), 121.92 (C8′), 124.17 (C1), 125.42 (C7′), 
126.12 (C6′), 126.92 (C3′), 127.91 (C5′), 128.12 (C9′), 134.72 
(C10′), 141.21 (C4), 148.63 (C3/C5), 152.81 (C1′), 165.26 (C7); 
HR-ESI-MS: m/z = 297.31 [M+H]+. 
 
2,6-dimethylphenyl 3, 4, 5-trihydroxybenzoate (7h) 
IR (KBr) ῦ/cm−1: 3510 (OH), 2910 (sp3 CH), 1734 (C=O), 1604 
(C=C), 1H NMR (methanol-d6, 500 MHz) δ/ppm: 2.36 (s, 6H, 
CH3), 6.54 (s, 2H, H2&H6), 6.99 (t, 1H, J = 7.4 Hz, H4′), 7.20 
(d, 2H, J = 7.4 Hz, H3′&H5′); 13C NMR (methanol-d6, 125 MHz) 
δ/ppm: 14.16 (CH3), 110.18 (C2&C6), 125.49 (C4′), 126.72 
(C1), 127.89 (C3′&C5′), 132.51 (C2′&C6′), 141.28 (C4), 148.61 
(C3&C5 ) 150.11 (C1′), 166.17 (C7); HR-ESI-MS: m/z = 275.29 
[M+H]+. 
 
2,3,6-trimethylphenyl 3, 4, 5-trihydroxybenzoate (7i) 
IR (KBr) ῦ/cm−1: 3480 (C=O), 2880 (sp3 CH), 1740 (C=O), 
1602, 1498 (C=C); 1H NMR (methanol-d6, 500 MHz ) δ/ppm: 
2.18 (s, 9H, CH3), 6.45 ( s, 2H, H4′& H6′), 7.24 (s, 2H, H2&H6); 
13C NMR (methanol-d6, 125.0 MHz ) δ/ppm: 12.37 (3-CH3), 
19.82 (4-CH3), 24.69 (6-CH3), 110.12 (C2&C6), 117.38 (C6), 
127.14 (C2′), 128.18 (C4′), 135.72 (C5′), 137.99 (C3′), 141.14 
(C4), 148.38 (C3&C5), 150.21 (C1′), 166.14 (C7); HR-ESI-MS: 
m/z = 289.32 [M+H]+. 
 
1-hydroxybenzotriazyl 3, 4, 5-trihydroxybenzoate (7j) 
IR (KBr) ῦ/cm−1: 3510 (C=O), 3020 (sp2 CH), 1730 (C=O), 
1604, 1494 (C=C), 1233 (CO); 1H NMR (methanol-d6, 500 
MHz ) δ/ppm: 6.55 (s, 2H, H2&H6), 6.87 (t, 2H, J = 7.4 Hz, 
H5′&H6′), 7.17 (d, 2H, J = 7.7 Hz, H4′&H7′); 13C NMR 
(methanol-d6, 125 MHz) δ/ppm: 110.13 (C2&C6), 118.27 
(C4′&C7′), 126.54 (C1), 127.98 (C5′&C6′), 134.83 (C3a), 141.16 
(C4), 144.58 (C7a), 147.27 (C3&C5), 165.91 (C7); HR-ESI-MS: 
m/z = 288.26 [M+H]+. 
 
2-methyl-8-quinolinyl 3, 4, 5-trihydroxybenzoate (7k) 
IR (KBr) ῦ/cm−1: 3502 (OH), 3040 (sp2 CH), 1745 (C=O), 
1601, 1499 (C=C); 1H NMR (methanol-d6, 500 MHz ) δ/ppm: 
2.61 (s, 3H, CH3), 6.62 (d, 1H, J = 9.0 Hz, H7′), 6.71 (s, 2H, 
H2&H6), 7.10 (d, 1H, J = 7.6 Hz, H3′), 7.21 (t, 1H, J = 7.0 Hz, 
H6′), 7.33 (d, 1H, J = 7.9 Hz, H5′), 7.79 (d, 1H, J = 8.3 Hz, H4′); 
13C NMR (methanol-d6, 125.0 MHz) δ/ppm: 25.67 (CH3), 
110.82 (C2&C6), 113.26 (C7′), 120.21 (C5′), 122.35 (C3′), 
125.48 (C1), 125.82 (C6′), 127.58 (C10′), 134.83 (C4′), 138.22 
(C9′), 141.52 (C4), 148.19 (C3&C5), 152.54 (C8′), 160.15 (C2′), 
166.45 (C7); HR-ESI-MS: m/z = 312.39 [M+H]+. 
 
2-methoxy-4-methylphenyl 3,4,5-trihydroxybenzoate (7l) 
IR (KBr) ῦ/cm−1: 3498 (OH), 2920 (sp3 CH), 1741 (C=O), 
1610, 1503 (C=C); 1H NMR (methanol-d6, 500 MHz) δ/ppm: 
2.20 (s, 3H, CH3), 3.62 (s, 3H, OCH3), 6.62 (d, 1H, J = 7.9 Hz, 
H5′), 6.75 (s, 1H, H3′), 6.80 (d, 1H, J = 8.0 Hz, H6′), 7.07 (s, 2H, 
H2&H6); 13C NMR (methanol-d6, 125.0 MHz) δ/ppm: 23.43 
(CH3), 56.08 (OCH3), 110.46 (C2&C6), 113.76 (C3′), 121.81 
(C5′), 123.18 (C6′), 126.13 (C1), 135.85 (C1′), 137.72 (C4′), 
139.42 (C4), 148.10 (C3&C5), 156.66 (C2′), 166.74 (C7); HR-
ESI-MS: m/z = 291.08 [M+H]+. 
 
3-phenylphenyl 3, 4, 5-trihydroxybenzoate (7m) 
IR (KBr) ῦ/cm−1: 3510 (OH), 3041 (sp3 CH), 1742 (C=O), 
1599, 1490 (C=C); 1H NMR (methanol-d6, 500 MHz) δ/ppm: 
6.58 (s, 2H, H2 & H6), 7.15 (d, 1H, J = 7.5 Hz, H4′), 7.24 (s, 1H, 
H2′), 7.35 (t, 1H, J = 6.9 Hz, H4ʺ), 7.56−7.40 (m, 4H, ArH), 7.63 
(d, 2H, J = 7.1 Hz, H2ʺ&H6ʺ); 13C NMR (methanol-d6, 125 
MHz) δ/ppm: 110.19 (C2&C6), 118.21 (C2′), 121.28 (C6′), 
125.16 (C4′), 127.59 (C2ʺ&C6ʺ), 127.59 (C4ʺ), 128.82 (C1), 
129.54 (C3ʺ&C5ʺ), 130.58 (C5), 136.32 (C1ʺ), 137.29 (C3′), 
141.14 (C4), 148.23 (C3&C5), 151.97 (C1′), 166.31 (C7); HR-
ESI-MS: m/z = 323.38 [M+H]+. 
 
2-isopropoxyphenyl 3, 4, 5-trihydroxybenzoate (7n) 
IR (KBr) ῦ/cm−1: 3505 (OH), 3040 (sp2 CH), 1739 (C=O), 
1604, 1501 (C=C), 1109 (CO); 1H NMR (methanol-d6, 500 
MHz) δ/ppm: 1.24 (d, 6H, J = 6.0 Hz, CH3), 4.57−4.51 (m, 1H, 
CH), 6.59 (s, 2H, H2&H6), 6.98 (t, 1H, J = 7.5 Hz, H5′), 
7.12−7.03 (m, H4′ & H6′), 7.20 (d, 1H, J = 6.2 Hz, H3′); 13C NMR 
( methanol-d6, 125.0 MHz ) δ/ppm: 23.13 (CH3), 26.46 
(CH3), 110.14 (C2&C6), 121.35 (C6′), 122.51 (C4′), 126.69 
(C3′&C5′), 141.53 (C4), 143.71 (C2′), 147.45 (C1′), 148.62 
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3-methoxyphenyl 3, 4, 5-trihydroxybenzoate (7o) 
IR (KBr) ῦ/cm−1: 3540 (OH), 1743 (C=O), 1610, 1503 (C=C), 
1250 (CO), 1H NMR (methanol-d6, 500 MHz ) δ/ppm: 3.80 
(s, 3H, OCH3), 6.47 (dd, 1H, J = 4.5 Hz, 2.3 Hz, H2′), 6.56−6.51 
(m, 1H, H4′), 6.98 (s, 2H, H2&H6), 7.02 (t, 1H, J = 8.5 Hz, H5′); 
13C NMR (methanol-d6, 125 MHz ) δ/ppm: 44.82 (CH2), 
55.48 (CH3), 108.61 (C2&C6), 113.37 (C4′), 114.33 (C2′), 
123.58 (C6′), 130.23 (C5′), 132.21 (C1), 136.78 (C1′), 141.24 
(C4), 149.83 (C3&C5), 160.17 (C3′), 201.74 (C7); HR-ESI-MS: 
m/z = 277.16 [M+H]+. 
Antimicrobial Activity 
Microbial Strains 
Samples were tested individually against all the 
microorganisms obtained from microbial collection of 
PCSIR antimicrobial laboratory Lahore and were 
maintained on Mueller-Hinton (MHA) and potato dextrose 
(PDA) agar slants at 4 °C. 
 
Preparation of Media 
Clear solutions of MHA and PDA were prepared by 
dissolving required quantities in deionized water and 
heating in conical flasks. Mueller-Hinton broth (MHB) and 
Sobouraud dextrose broth (SDB) solutions were prepared 
in deionized water in test tubes. All the media flasks and 
test tubes were plugged with cotton wool and sterilized in 
an autoclave for 15 minutes at 121 °C. To avoid 
contamination, sterilized agar medium (20.0 ml) was 
poured aseptically into sterilized petri dishes. On 
solidification, they were incubated for 24 h at 37 °C in an 
inverted position to avoid evaporation of water from 
medium within the plates. Uncontaminated MHA and PDA 
plates were used for culturing bacteria and fungi. 
 
Preparation of Inoculum 
Bacterial strains were cultured from stock slants (kept at 4 
°C ) in MHB for 24 hat 37 °C. Inoculum of each strain was 
prepared by diluting the active and pure culture with 
deionized water until it achieved the turbidity of the 0.5 
McFarland barium standard. Test fungi strains were 
cultured on PDA for 3−5 days at 30 °C to induce spore 
formation. Turbidity was adjusted to the 0.5 McFarland 
barium standard by diluting with deionized water. 
 
Agar Well-diffusion Protocol[23] 
Autoclaved MHA plates were seeded onto the surface with 
24 hour old broth culture of different bacteria. Samples 
were dissolved thoroughly in DMSO and different 
concentrations were prepared by serial dilution method. 
Four wells of 8.0 mm were cut out in each plate using sterile 
cork borer. Plant extracts of different concentrations (60.0 
µL) were added carefully in each plate and were incubated 
for 24 h at 37 °C. Ciprofloxacin (standard antibiotic) was 
used as positive control, while DMSO served as negative 
control. 
 For antifungal activity, diluted solution of fungi was 
swabbed onto the entire surface of PDA plates. The 
inoculated plates were dried, followed by carving four wells 
on each plate by sterilized cork borer. Different 
concentrations of each sample (60.0 µL) were poured 
carefully in plates by sterilized micropipettes and were 
incubated for 48 h at 30 °C. Reference drug was nystatin 
while DMSO served as negative control. Three plates were 
inoculated for each microbe. Antimicrobial potential was 
estimated from diameter of clear zone around each well. 
 
Minimum Inhibitory Concentration (MIC) and Minimum 
Mactericidal/Fungicidal Concentration Protocol[24,25] 
A 24 h bacterial culture in MHB and Tween 80 (0.5 % v/v) 
was diluted 1000X. Sample solution (0.3 ml) was added to 
diluted culture (2.7 ml) and bacterium growth was assessed 
from turbidity after 24 h incubation at 37 °C. Fungi was 
cultured for 2−3 days at 30 °C in SDB with Tween 80 (0.5 % 
v/v). 1000X diluted culture (2.7 ml) was added to test 
sample solution (0.3 ml) and incubated for 48 h at 30 °C to 
check the appearance of turbidity. MIC was taken as that 
conc. of the sample where no turbidity appears in the 
culture medium. For estimation of MBC/MFC an aliquot of 
each tube where no microbial growth was observed in prior 
test was swabbed on MHA plates in case of bacteria and on 
PDA plates in case of fungal strains thoroughly and 
incubated under previously described growth conditions. 
The lowest concentration that retarded bacterial/fungal 
growth was recorded as MBC/MFC. 
Antioxidant Activity 
DPPH Scavenging Assay 
DPPH radical-quenching ability of samples was evaluated 
by applying previously reported.[26] 
 
ABTSDecolorization Assay 
ABTS·+decolorization potential was evaluated by applying 
previously reported method.[26] 
 
Anti-lipid Peroxidation Assay 
Anti-lipid peroxidation activity of samplesand reference 
standards was assessedby applying previously reported 
method.[26] 
 
RESULTS AND DISCUSSION 
Chemistry 
The synthetic route for the preparation of GA esters is 
presented in Scheme 1. To afford compounds 7a-7o, GA (1) 
was first esterified as propyl ester (2) to avoid side 
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by benzyl chloride in DMF to produce propyl 3, 4, 5-
tribenzyloxy benzoate (3) with 73 % yield prior to activation 
as acid chloride. Later, saponification using NaOH in 
methanol and water was employed to get 3,4,5-
tribenzyloxy benzoate (4). Intermediate acid chloride (5) 
was obtained by treating with thionyl chloride, followed by 
esterification in the presence of Et3N in dry anhydrous 
chloroform under refluxing condition to give corresponding 
benzylated esters (6a-6o). Deprotectionusing 
palladium/charcoal activated in hydrogen atmosphere at 
room temperature afforded compounds 7a-7o. We 
obtained fifteen gallic acid derivatives that together with 
gallic acid were subjected to in vitro assessment of 
antimicrobial potential against an array of microbes. 
Electron transfer (ET) and hydrogen atom transfer (HAT) 
antioxidant assays were employed to evaluate antioxidant 
potential of the synthesized compounds. 
Antimicrobial Activity 
The antimicrobial activity of synthesized novel gallic acid 
derivatives was assessed qualitatively and quantitatively in 
vitro by measuring zone of inhibition and MIC and MBC 
values. For this purpose three gram-positive bacteria- 
Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 
25923) , Bacillus licheniformis (PCSIR-B-252); five gram-
negative bacteria-Pseudomonas aeruginosa (ATCC 27853), 
Eschrecia coli (ATCC 25922), Pseudomonas aeruginosa 
(ATCC 27853), Salmonella typhimurium (ATCC 14028), 
Enterobacter aerogenes (ATCC 13043), Proteus mirabilis 
(ATCC 29245), and two fungal strains- Candida albicans 
(ATCC 10239) and Aspergillus niger (PCSIR-M-204) were 
employed using well-diffusion method and results are 
represented in the Table 2 along with reference drugs i.e. 
ciprofloxacin and nystatin as positive control. Initially, lead 
compound gallic acid and derivatives 7a−7o were screened 
at four different concentrations 2.0, 1.0, 0.5, 0.25 mg mL−1 
per well for qualitative assessment of antimicrobial and 
antifungal potency. Zone of inhibition presented in Table 1 
indicated that microbes exhibited variable sensitivity 
towards tested compounds, though most of the derivatives 
were more effective against gram-positive pathogens in 





































Scheme 1. Synthetic route of novel gallic acid derivatives 7a−7o, Reagents and conditions: (a) SOCl2, CH3CH2CH2OH, 70 °C, reflux 
6 h; (b) C6H5CH2Cl, K2CO3, DMF, reflux 4 h; (c) CH3OH, NaOH, reflux 4 h; (d) SOCl2, C5H5N, C6H6, reflux 3 h; (e) ROH (Table 1), 
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strains were least susceptible to the synthesized derivatives 
nevertheless they were immune towards gallic acid and did 
not exhibit antifungal potential under the test conditions. 
In general compounds were more effective against A. niger 
than C. albicans. Activities obtained through well diffusion 
method were confirmed by evaluating MIC and MBC 
values. 
 Table 3 represents the MIC (minimal inhibitory 
concentration) of the synthesized derivatives. It is the 
lowest concentration of antimicrobial agent that could 
visibly inhibits microbial growth without giving any 
indication whether mode of action was bacteriostatic or 
bactericidal. Tested compounds exhibited better inhibition 
of bacteria than fungal strains. It is clear that compounds 
7a and 7c showed highest antimicrobial potency with MICs 
0.015 mg mL−1 and 0.031 mg mL−1 for tested gram positive 
microbes as compared to lead i.e. upto 16 and 8 fold more 
potent than parent. In general inhibition was one fold lower 
for S. aureus than B. subtilis and B. licheniformis. According 
to MIC data obtained it was observed that majority of the 
compounds inhibited all the listed microbes modestly with 
some exceptions for instance, 7l showed potent 
antimicrobial action against B. subtilis with lowest MIC 
value of 0.015 mg mL−1 that could be an interesting starting 
Table 1. Physical and chemical data of derivatives 7a−7o 
Compound R M.P. / °C 
% 
Yield 
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point in the pursuit of specific antimicrobial agent targeting 
B. subtilis.  
 Antimicrobial tests carried out against gram negative 
bacteria showed that in general they were much resistant 
against synthesized compounds, though diversity in MICs 
was obtained as shown in Table 3. Compound 7c emerged 
as most potent agent against all the tested gram-negative 
microbes except P. aeruginosa with MICs 0.015 mg mL−1. P. 
mirabilis was found to be least susceptible as a much higher 
MICs were observed against it and almost all the 
compounds except 7c exhibited weak inhibitory profile. 
Whereas E. coli was found to be most susceptible gram-
negative bacteria among the tested microbes. In general, 
synthesized compounds appear to be more active against 
gram positive strains while gram negative bacteria showed 
resistance with higher MICs. 
 Unfortunately most of the synthesized compounds 
were least effective against tested fungi (Table 3) with very 
high MICs in the range of 0.5−2.0 mg mL−1.Gallic acid did 
not show activity against the tested fungal strains that is in 
accordance with the previous reports.[27] In comparison to 
lead, introduction of different moieties remodeled 
behavior of the derivatives and they elicited antifungal 
response though no significant activity was observed. 
 Figure 1 shows the correlation between MICs of 
synthesized compounds against different sets of microbes 
as represented by plotmatrix graphs in a view to evaluate 
their pattern of activity. In the figure, rows represent 
plotmatrices for MICs, whereas the columns represent 
gram-positive, gram-negative and fungal strains 
respectively. The scatter plot in each image presents the 
correlation between the MICs of two microbes. Pearson 
Table 2. Zone of inhibition (mm) of the compounds 7a−7o 
Compounds 
Gram-positive bacteria Gram-negative bacteria Fungi 
a b c d e f g h i j 
1 9.33±0.3(a) 9.66±0.3 11.1±0.7 ‒ ‒ ‒ ‒ ‒ NA NA 
7a 13.8±0.4 13.5±0.7 11.4±0.2 9.33±0.2 14.2±0.4 9.66±0.3 13.1±0.3 12.3±0.6 ‒ ‒ 
7b 11.3±0.3 9.66±0.2 10.7±0.5 9.33±0.3 12.4±0.3 10.3±0.6 9.33±0.6 12.5±0.7 ‒ ‒ 
7c 13.5±0.4 14.5±0.3 11.8±0.3 12.3±0.6 13.5±0.6 10.6±0.7 14.1±0.3 13.5±0.4 ‒ ‒ 
7d 13.4±0.3 14.6±0.5 15.2±0.2 9.33±0.1 13.4±0.4 10.4±0.2 12.3±0.3 13.4±0.6 11.4±0.5 10.4±0.5 
7e 11.7±0.5 14.3±0.3 13.3±0.2 10.2±0.5 15.2±0.6 10.9±0.3 13.3±1.0 13.1±1.2 ‒ ‒ 
7f 16.8±1.1 13.6±0.2 15.2±0.6 10.2±0.7 15.5±0.2 9.33±0.3 13.2±0.4 11.3±0.5 ‒ ‒ 
7g 10.5±0.4 9.33±0.3 14.6±0.4 10.1±0.6 11.3±0.6 NA 10.2±0.5 11.5±0.2 ‒ ‒ 
7h 10.4±0.5 13.1±0.2 12.3±0.5 ‒ 12.4±0.6 9.66±1.3 12.2±1.3 10.1±1.0 ‒ ‒ 
7i 10.3±0.8 13.5±1.4 13.4±0.4 ‒ 14.7±0.3 ‒ 12.1±1.4 11.4±0.5 ‒ ‒ 
7j 15.4±0.6 14.4±0.4 12.4±0.5 9.33±0.1 14.1±0.6 11.2±0.5 12.2±0.7 14.5±0.2 ‒ ‒ 
7k 14.3±0.3 13.7±0.2 12.4±0.6 10.3±0.4 13.1±0.3 ‒ 13.1±0.7 13.2±0.4 ‒ ‒ 
7l 11.5±0.4 13.4±0.3 12.4±1.1 ‒ 10.2±0.3 9.33±0.5 10.4±0.4 11.2±0.4 ‒ ‒ 
7m 9.33±0.5 12.4±0.4 13.2±0.1 ‒ 10.3±0.3 ‒ NA 9.33±0.3 ‒ ‒ 
7n 14.3±0.2 14.4±0.5 15.4±0.5 ‒ 12.3±0.7 ‒ 11.3±0.5 11.6±0.7 ‒ ‒ 
7o 13.1±0.3 13.3±0.6 13.5±0.6 ‒ 11.4±0.4 ‒ 9.33±0.4 9.33±0.2 ‒ ‒ 
Ciprofloxacin 32.3±0.3 29.6±0.1 31.3±0.4 26.4±0.3 24.5±0.3 22.8±0.4 33.8±0.8 35.4±0.6   
Nystatin ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 27.3±0.6 25.5±0.7 
DMSO ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ ‒ 
(a) Diameter of inhibition zone includes the diameter of well (8.0 mm); ‒: absence of measurable inhibition;NA: not active; ±: Standard Deviation; a: B. subtilis;  
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coefficient “r” of significantly correlated results are shown 
in the figure. It could be seen in Figure 1(a) that MICs are 
significantly correlated for gram-positive microbes and 
highest correlation coefficient (r = 0.9877) was found 
between MIC data of S. aureus and B. subtilis. Similarly high 
correlation among MICs of most of the gram-negative 
microbes was found as shown by Figure 1(b) revealing 
almost same level of effectiveness of synthesized 
compounds against them. Similarly difference in the 
behavior of the compounds against tested fungal strains is 
depicted by Figure 1(c) that shows poor correlation 
between observed MICs. It could be inferred from these 
graphs that tested compounds exhibited broad spectrum 
activity against tested bacterial strains while inhibited 
fungal strains weakly. Furthermore the histogram plots in 
the diagonal give us insight regarding probability  
Table 3. MIC (MBC) mg mL−1 of the compounds 7a−7o 
Compounds 
Gram-positive Microbes Gram-negative Microbes Fungi 





































































































































































































































































































































MIC: Minimum inhibitory concentration; MBC: Minimum bactericidal concentration; NA: not active; a: B. subtilis; b: S. aureus; c: B. licheniformis; d: P. aeruginosa; 
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Figure 1. Polymetrix graphs showing MICs scatter plots and corresponding correlation coefficient ‘r’ of (aʹ): Gram-positive 





 L. SHERIN et al.: Biological Evaluation of Novel Gallic Acid Analogues 561 
 




distribution of MICs for each microbe. The height of each 
bar shows the frequency of a particular MIC appearing in 
the data set for different compounds.  
 MBC is the lowest concentration of the antibiotic 
required to kill the microbes. Analysis of Table 2 reveals 
that there are many compounds that were effective on the 
basis of MICs but failed to prove potency against the tested 
microbes on the basis of MBCs. 
 Weibull distribution approach is used to give an 
overview of microbial resistance towards tested 
compounds via distribution probability of MBCs. The points 
on the plot exhibit the probability distribution of each MBC 
value for all the tested microbes in the data set. In Figure 2 
x-axis represents the MBCs from a range of 0.0004 to 1.0 
mg mL−1 and y-axis represents probability of their 
occurrence for each microbe. The slope of the best-fit 
straight line is determined through the data using linear 
regression. We can estimate all the statistical properties 
through this plot e.g. skewness of the data, parameter 
estimate value, median, microbial resistance towards 
tested compounds etc. For example in gram-positive 
microbes probability distribution of MBC value 0.062 mg 
mL−1 is highest i.e. 0.294 s for B. subtilis whereas 0.5 mg 
mL−1 showed highest distribution for S. aureus and B. 
licheniformis. Figure 2(c) shows that gram-negative strains 
were more resistant against GA derivatives as most 
frequently observing MBCs are 0.5 and 1.0 mg mL−1. For the 
fungal strains, most of the MBCs were not detected as they 
did not fall in the tested concentration range. 
 Mode of antimicrobial activity is represented in 
Figure 3. Generally an antibiotic is regarded bacteriostatic 
if MBC/MIC ratio is greater than MICx3.[28] Heatmap graphs 
of data revealed that mode of action of many compounds 
was bactericidal as MBCs were two fold higher than MICs 
while derivatives having ratio three or higher folds were 
bacteriostatic in nature. 
 Figure 4(a′) presents the thin plate interpolant for 
gram-positive microbes. The slope of plate is relatively 
increasing for increasing MBCs, since the ratio increases 
likewise. A good percentage of points lie on or below the 
plane MBC/MIC = 2. The graph 4(b′) presents the thin plate 
interpolant for gram-negative microbes. The graph has a 
tale towards the increasing values of MIC. This shows that 
the spread is rational with respect to increasing values of 
MBC but irrational for increasing values of MIC. A good 
percentage of points lie on or below the plane MBC/MIC = 
4. The graph 4(c′) presents the thin plate interpolant for the 
tested fungal strains. There is a twist in the plate relative to 
increasing values of MBC. Only a few points lie on or below 
the plane MBC/MIC = 2. From the three dimensional 
presentation above, we can see that the MBC/MIC ratio is 
lowest for fungal microbes. For other two cases, its values 
ranged from 1 till 8. The spread of the data relative to MIC, 
MBC and their corresponding ratio helps to depict the 









Figure 2. Weibull distribution graphs of MBCs of (aʹ): Gram-
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The surface plotted presents the deviation of the data 
points relative to increasing values of MIC and MBC. In 4(a′) 
the data points are nicely scattered, whereas in case 4(b′), 
the spread is complex and in case 4(c′) it is hard to predict 
the relation between MIC and MBC from their surface plot. 
Structure-Activity Relationship 
From analysis of antimicrobial activity results of 
synthesized gallic acid derivatives, following assumptions 
regarding structure activity relations can be made: 
i. Structural modifications in parent compound have 
resulted in enhanced biological activities specifically 
against bacterial strains. Poor antifungal activity of 
lead as well as derivatives is in accordance to Goker 
et al.[29] work that reported the ineptness of 
introduction of amide, carboxylic or ester linkage for 
antifungal power enhancement. 
ii. In general, substituent grafting had much more 
pronounced impact on therapeutic value of the 
synthesized compounds than mere introduction of 
ester linkage in the parent molecule. Activity pattern 
observed in this study indicated that electron-
withdrawing substituent exhibited higher activity 
against tested microbial strains than electron-
donating substituent. These findings are in 
consistent with the work of Sherma et al.[30] 
iii. Halogen substituted, particularly, chloro derivatives 
of alkyl esters proved to be more potent 
 





Figure 3. Bactericidal/bacteriostatic activity of the synthesized compounds 7a−7o against (aʹ):Gram-positive bacteria; (bʹ):Gram-
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antibacterial agent. Thus compounds 7a and 7c 
exhibited highest broad spectrum activity though 
they were not handy against tested fungi. 
Apparently ortho or para position of substituent had 
no significant impact on activity. 
iv. Aryl esters exhibited much better antimicrobial 
profile as compared to GA. Comparison of data 
suggested that whether substituted or unsub-
stituted both aryl moieties played vital role in 
improving the antimicrobial potential. It is assumed 
that aromatic ring enhances the drug binding with 
target by increasing its lipophilicity. 
v. It could be deduced from the results that structural 
requirements are different for drug binding to 
bacterial and fungal targets as only NO2 substituted 
compound have shown reasonable antifungal 
activity among all the tested compounds. These 









Figure 4. 3D surface plots showing interrelation of MIC, MBC and MBC/MIC values for (aʹ): Gram-positive bacteria; (bʹ): Gram-
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Antioxidant Activity Evaluation 
The antioxidant capacity of the synthesized derivatives was 
evaluated using ET and HAT antioxidant assays. The 
disagreement between antioxidant capacities obtained 
from different assays indicates that each class of assays 
determines different aspects of antioxidant capacity by 
employing different radicals and reaction mechanism. 
 Results of electron transfer based assay i.e. DPPH 
radical scavenging and ABTS decolorization assay are 
shown in Table 4. All the compounds exhibited different 
propensity towards free radical quenching, the maximum 
values in DPPH assay were found for 7d and 7f. The 
calculated IC50 values for compounds varied from 1.12 to 
57.7 µg ml−1. It was found that many derivatives (7a−7f, 7j) 
were more active than lead in DPPH quenching and showed 
much low IC50 values. For ABTS assay IC50 values ranged 
from 1.19 to 9.93 µg ml−1. Most efficient compounds with 
highest values were 7d and 7a. In both the assays7k 
showed the poorest results with highest IC50 values. 
Similarity of the results can be explained as in both of these 
assays reaction mechanism is based on electron transfer 
and measurement of antioxidant potential is associated 
with exogenous reduction of free radicals such as DPPH• 
and ABTS+•. A careful analysis of results reveals that 
grafting a substituent on ester moiety had significant 
impact on radical quenching capacity of the synthesized 
compounds. Data shows that introduction of halogen atom 
or nitro group enhanced the built-in antioxidant power 
many folds. It is speculated that electron-withdrawing 
character of the substituent might have augmented the 
stability of phenoxide ion formed during the radical 
quenching process. Electron -withdrawing substituent cut 
down the electron density on pyrogallol moiety and tend to 
stabilize the phenoxide ion formed, resulting in higher 
antioxidant capacity. Inversely electron donating groups 
destabilize the phenoxide ion and hence decline 
antioxidant power of the compound. 
 In anti-lipid peroxidation assay, results showed that 
compounds 7j, 7c and 7f provided highest protection 
against peroxidation with lowest production of malon-
dialdehyde (MDA). In comparison to gallic acid, almost all 
the derivatives generated a significant decrease in MDA 
concentration. A significant difference in shielding against 
lipid peroxidation may be attributed to the structural 
differences in derivatives. It was found the compounds 
bearing electron-withdrawing substituent displayed much 
better protection against lipid damage; hence can impart 
better therapeutic benefits against ROS mediated lipid 
oxidation. This assay is based on hydrogen atom transfer 
(HAT) method that measure antioxidant potency on the 
basis of capturing endogenous radicals acting on oxidized 
targets. Though reaction mechanism is complex but 
inherent advantage of this assay is involvement of 
physiological radicals in contrast to ET assays. These 
findings show significant potential of some of the gallic acid 
esters as valuable natural antioxidant molecules. 
Table 4. In vitro DPPH scavenging, ABTS·+decolorization, and anti-lipid peroxidation activities of gallic acid esters (7a−7o) 
Half Efficiency Conc. (IC50)a 
Compounds 
DPPH scavenging activity  
(µg ml−1) 
ABTS+ decolorization 
activity (µg ml−1) 
Anti-lipid peroxidation activity  
(mg ml−1) 
1 2.38±0.05b 1.60±0.08b 2.22±0.02b 
7a 1.33±0.10 1.19±0.09 0.24±0.04 
7b 1.45±0.11 1.44±0.20 0.26±0.03 
7c 1.43±0.07 1.35±0.07 0.21±0.02 
7d 1.12±0.13 1.14±0.18 0.33±0.01 
7e 1.37±0.15 1.25±0.05 0.25±0.02 
7f 1.23±0.06 1.21±0.23 0.24±0.03 
7g 18.7±0.65 1.93±0.08 0.48±0.01 
7h 19.4±0.88 1.54±0.25 0.41±0.13 
7i 19.9±0.43 1.65±0.55 0.44±0.02 
7j 1.45±0.04 1.51±0.07 0.20±0.40 
7k 57.7±0.60 9.93±0.40 0.50±0.01 
7l 17.8±0.68 1.46±0.04 0.40±0.02 
7m 18.3±0.20 2.00±0.06 0.45±0.01 
7n 18.4±0.44 1.26±0.09 0.39±0.01 
7o 18.7±0.30 1.20±0.04 0.39±0.11 
trolox 6.17±0.02 3.86±0.03 0.08±0.03 
a IC50 is the conc. of the compound that causes 50 % decline of initial DPPH, ABTS·+ or TBARS conc.; 
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In conclusion, a series of new gallic acid esters 7a−7o was 
synthesized. Pharmacological assessment was undertaken 
to evaluate the impact of structural modification and 
substituent for their antibiotic and antioxidant potency. In 
general bacteria were more sensitive than fungal strains on 
these compounds. Most of the derivatives displayed 
moderate to good broad spectrum activity towards tested 
microbial panel but did not express substantial action 
against fungal strains. Most effective compounds found 
were 7a, 7c and 7d. Significant enrichment of antimicrobial 
power of synthesized compounds can be attributed to the 
presence of electron-withdrawing groups. Particularly, 
grafting of chloro group amplified the inhibitory action 
many folds. Similar pattern was observed in antioxidant 
activity as it was much upgraded by implanting electron 
withdrawing substituent onto gallic acid architecture. In 
comparison to inactive lead, quite high MICs of derivatives 
against fungal strains indicate further structural 
modification of these compounds for improved antifungal 
activity. 
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